15 April 2022This recent study investigated the relationship between the timing of steroid exposure preceding ICI administration and subsequent treatment outcomes in melanoma. The study concludes that steroid exposure within 3 months of initiating ICIs was associated with increased mortality up to 6 months after ICI.
15 April 2022Authors of this recent study propose selective mRNA processing and translation by U2AF homology motif kinase 1 (UHMK1) constitutes a mechanism of non-genetic resistance to targeted therapy in melanoma by controlling metabolic plasticity induced by therapy.
15 April 2022Authors of this recent study performed integrative genomic and clinical profiling of acral melanomas from 104 patients. The results provide insights into the etiology of acral melanoma and implicate LZTR1 as a key tumor promoter and therapeutic target.
14 April 2022The Cancer Control Agency Te
Aho o Te Kahu continues to monitor the impact of COVID-19 on cancer diagnostic
and treatment services. The most recent report includes DHB data up until
the end of February 2022.
31 March 2022According to this recent epidemiological assessment, melanoma remains an important challenge to cancer control and public health globally, especially in fair-skinned populations of European descent. The highest incidence rates were observed in Australia/New Zealand. Mortality rates peaked at 5 per 100 000 person-years in New Zealand.
18 March 2022In this issue of EMBO Molecular Medicine, Diazzi et al (2022) identify a mechanism regulating MAPKiinduced phenotypic plasticity and resistance, providing evidence to support the use of an anti-fibrotic drug as a potential novel combinatorial therapeutic approach in melanoma treatment.
18 March 2022According to this recent study, the implementation of a ban on commercial indoor tanning across England with an accompanying public information campaign would be an effective use of healthcare resources.
18 March 2022The objective of this study was to assess the concordance of response between the index lymph node (ILN) and the total lymph node bed in a larger clinical trial population. Results of the study suggest that the pathologic response of the ILN may be considered a reliable indicator of the entire therapeutic lymph node dissection (TLND) specimen response and may support the ILN response-directed omission of TLND in a prospective trial.
18 March 2022This systematic review was conducted to investigate the outcomes of digital interventions that promote sun protection and skin self-examination (SSE). Almost all studies found digital interventions to be equally or more effective compared to non-digital interventions.
15 March 2022Authors of this paper describe the state of the science of neoadjuvant systemic therapy (NAST) for melanoma, focusing on the surgical aspects and the key role of the surgical oncologist in this treatment paradigm. The paper summarizes the past decade of developments in melanoma treatment and the current evidence for NAST in stage III melanoma specifically.